ASCO 2019 | The ECOG-ACRIN E2810 study: pazopanib for patients with mRCC

Elizabeth Plimack

Elizabeth Plimack, MD, MS, of the Fox Chase Cancer Center, Philadelphia, PA talks about The ECOG-ACRIN E2810 (NCT01575548) study that looks at pazopanib for patients with metastatic renal cell carcinoma (mRCC). This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

Share this video  
Similar topics